[Advances in therapeutic strategies for multiple myeloma].
Multiple myeloma (MM) remains an incurable plasma cell dyscrasia characterized by bone marrow failure, bone disease, renal disease and other complications. The clinical pictures show extensive diversity which is based on complex cytogenetic abnormalities, and lot of interactions between myeloma cell and bone marrow stroma. Recently, advances in understanding the biology of myeloma including the function of proteasome, molecular chaperons on the folding of intracellular proteins as well as signal transduction pathway, apoptosis-inducing cascade and oncogenomics, have brought about the development of several new therapeutic strategies. This review summarizes the major innovative agents in this field and discuss the future directions.
Miwa
Akiyoshi
A
Dept. of Hematology, International Medical Center of Japan.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000187:drug effects; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D002450:Cell Communication / Q000187:drug effects; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000473:pathology; D061988:Proteasome Inhibitors; D011719:Pyrazines / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001897:Boronic Acids; D061988:Proteasome Inhibitors; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide